Latest publications
"Suffocating" tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy.
- Tumor Immunotherapy and Microenvironment
2021 Sep. Oncoimmunology.10(1):1968611.
Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy.
- Tumor Immunotherapy and Microenvironment
2021 Jul. Oncogene.40(28):4725-4735. Epub 2021 Jun 21.
Epithelial to mesenchymal transition regulates surface PD-L1 via CMTM6 and CMTM7 induction in breast cancer.
- Tumor Immunotherapy and Microenvironment
2021 Mar. Cancers.13(5):1165.
CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6.
- Immuno-Pharmacology and Interactomics
- Tumor Immunotherapy and Microenvironment
- Allergy and Clinical Immunology
- Personalized Therapy Discovery
2021 Mar. Cancers.13(5):1054.
Targeting cytoprotective autophagy to enhance anticancer therapies.
- Tumor Immunotherapy and Microenvironment
2021 Feb. Front Oncol.11:626309.
Selection of tumor-resistant variants following sustained natural killer cellmediated immune stress.
- Tumor Immunotherapy and Microenvironment
2021 Feb. Oncol Rep.45(2):582-594. Epub 2020 Nov 27.
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition).
- NORLUX Neuro-Oncology Laboratory
- Tumor Immunotherapy and Microenvironment
- Digital Medicine
2021 Jan. Autophagy.17(1):1-382. Epub 2021 Feb 8.
Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34.
- Tumor Immunotherapy and Microenvironment
2020 Nov. Autophagy.(11):2110-2111. Epub 2020 Sep 5.
The 'Holy Grail' in immuno-oncology: AC BioScience SA is aiming to potentiate anti-PD-1 therapy efficacy through tumor cell conditioning strategy.
- Tumor Immunotherapy and Microenvironment
2020 Oct. Chimia.74(10):771-775.
Impact du ciblage du domaine de liaison de HIF-1alpha avec HIF-1beta sur le paysage immunitaire du mélanome. (Doctoral thesis)
- Tumor Immunotherapy and Microenvironment
2020 Oct. Paris: University Paris-Saclay, 2020. 215 p.
Firing up the cold tumors by targeting Vps34.
- Tumor Immunotherapy and Microenvironment
2020 Aug. OncoImmunology.9(1):1809936.
Hypoxia-induced autophagy drives colorectal cancer initiation and progression by activating the PRKC/PKC-EZR (ezrin) pathway.
- Tumor Immunotherapy and Microenvironment
- Multiomics Data Science
- Integrated BioBank of Luxembourg
- Luxembourg Center of Neuropathology
2020 Aug. Autophagy.16(8):1436-1452. Epub 2019 Nov 27.
Checkpoint inhibitors and engineered cells: new weapons for natural killer cell arsenal against hematological malignancies.
- Tumor Immunotherapy and Microenvironment
2020 Jun. Cells.9(7).
The emerging impact of autophagy on the antitumor immune response. In Autophagy in immune response: Impact on cancer immunotherapy. 1st ed. (Book Chapter)
- Tumor Immunotherapy and Microenvironment
2020 May. Chouaib S, ed. London: Academic Press, 2020. p.109-117. (Sensitizing Agent-Canc Resistant-Cell Mediated Immtherap, Vol.1). ISBN 978-0-12-819609-0.
Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.
- Tumor Immunotherapy and Microenvironment
2020 May. Sci Adv.6(18):eaax7881.
Assessing autophagy in archived tissue or how to capture autophagic flux from a tissue snapshot.
- Tumor Immunotherapy and Microenvironment
2020 Mar. Biology.9(3):59.
Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges.
- Tumor Immunotherapy and Microenvironment
2019 Sep. Cells.8(9).
Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints.
- Tumor Immunotherapy and Microenvironment
2019 Aug. Cancer Lett.458:13-20. Epub 2019 May 25.
The distinct roles of CXCR3 variants and their ligands in the tumor microenvironment.
- Immuno-Pharmacology and Interactomics
- Tumor Immunotherapy and Microenvironment
- NORLUX Neuro-Oncology Laboratory
2019 Jun. Cells.8(6).
Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
- Tumor Immunotherapy and Microenvironment
- NORLUX Neuro-Oncology Laboratory
2019 Apr. Int J Cancer.144(7):1735-1745. Epub 2018 Dec 11.